BreakThrough Digest - cancer,  medical information

BreakThrough Digest offers current medical news and health articles on medical breakthroughs, medical research and health information on clinical trials, cancer, Alzheimer's, stem-cell research, heart disease, diabetes and more.



HOME

RECENT HEADLINES

NEW RESEARCH

CLINICIAL TRIALS

COMMENTARY

FDA NEWS DIGEST

ADVERTISE

RESOURCES

Quick Links to:

  - Medical Journals
  - Government Health Sites
  - Pharmaceutical Companies
  - Archives
  - A Challenge for Health IT
  - Mobile Edition

Advertisers...

Neprinol
- exclusive distributors of pharmaceutical-grade products including neprinol, syntol, and devacor

Chelation - cardio renew is 100% pure edta providing cardiovascular cleansing by oral chelation.

New hope for Hepatitis C research

The mystery surrounding Hepatitis C, a disease that affects millions of people worldwide, is one step closer to being solved.

In a paper published in the August edition of Journal of Virology, scientists describe how they replicated, or reproduced the hepatitis C virus (HCV) in mouse cells. Working with different models, they showed a gene called protein kinase R (PKR) blocked the replication of HCV in mice.

"When a person becomes infected with HCV, the immune system produces a protein called interferon to fight the infection," said co-author and Director of the Monash Institute of Medical Research, Professor Bryan Williams.

"We now know genes interferon stimulates PKR to try to stop the virus spreading throughout the body."

HCV replicates at a very high rate – approximately one trillion viral particles are produced each day in an infected person. Professor Williams' research will provide a better understanding of how this replication occurs and how and why PKR blocks the production of the virus.

Hepatitis C affects 210,000 Australians. Worldwide, it is estimated more than 170 million people suffer from the disease. The virus attacks the liver, causing flu-like symptoms, fevers, abdominal pain, depression, and for two-thirds of patients, chronic liver disease.

The discovery may also shed light on why some hepatitis C patients respond better to treatment than others.

"As there is no vaccine or cure for HCV, the only treatment on offer for patients is interferon therapy, which aims to slow the progression of the disease. However, there are six different genotypes, or strains of HCV, which all react differently to treatment," Professor Williams said.

"We can now explore why some strains are more sensitive to interferon therapy, and how we can adapt treatment to the different strains of the disease."

"Our research is still in the early stages, but the research model we have created will be a valuable tool in understanding the underlying mechanisms of chronic HCV infection, and how the virus responds to interferon treatment" said Professor Williams.

 

 

Google

BreakThrough Digest
Copyright 2007 BreakThrough Digest
BreakThrough Digest subscribes to the eHealth Code of Ethics

 

medical new and medical breakthroughs health information and health articles about medicine on cancer, heart disease, diabetes and stem cell research

medrocket award

Trute